Symbols / EGRX $0.25 +0.00% Eagle Pharmaceuticals, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • PNK
EGRX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Michael Graves
Exch · Country PNK · United States
Market Cap 3.29M
Enterprise Value 66.19M
Income 11.95M
Sales 257.55M
FCF (ttm) 38.31M
Book/sh 19.25
Cash/sh 1.18
Employees 134
Insider 10d —
IPO Feb 12, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 1.32
Forward P/E 0.07
PEG —
P/S 0.01
P/B 0.01
P/C —
EV/EBITDA 1.06
EV/Sales 0.26
Quick Ratio 1.51
Current Ratio 2.16
Debt/Eq 28.75
LT Debt/Eq —
EPS (ttm) 0.19
EPS next Y 3.48
EPS Growth —
Revenue Growth -12.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-08-08
Earnings (prior) 2023-08-08
ROA 6.63%
ROE 4.88%
ROIC —
Gross Margin 69.84%
Oper. Margin 15.94%
Profit Margin 4.64%
Shs Outstand 13.16M
Shs Float 5.91M
Insider Own 0.00%
Instit Own 55.20%
Short Float 4.19%
Short Ratio 3.91
Short Interest 350.53K
52W High 3.87
vs 52W High -93.54%
52W Low 0.00
vs 52W Low 24,900.00%
Beta 0.60
Impl. Vol. —
Rel Volume 0.15
Avg Volume 657.00
Volume 100.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.25
Price $0.25
Change 0.00%
About

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.25
Latest analyst target
3. DCF / Fair value
$52.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.25
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-08-09 down Piper Sandler Neutral → Underweight $17
2020-03-02 main Cantor Fitzgerald — → Neutral $46
2019-03-22 main Mizuho Neutral → Neutral $41
2018-10-31 down Piper Sandler Overweight → Neutral $54
2018-09-21 main Cantor Fitzgerald Overweight → Overweight $80
2018-06-12 init Cantor Fitzgerald — → Overweight $81
2018-06-11 up Mizuho Underperform → Neutral —
2017-01-09 down Mizuho Neutral → Underperform $64
2016-11-03 up Mizuho Neutral → Buy —
2016-11-02 main William Blair — → Outperform —
2016-06-20 down Mizuho — → Neutral —
2015-12-09 init Mizuho — → Buy $112
2015-12-08 init Mizuho — → Buy $112
2015-08-12 main Piper Sandler — → Overweight $120
2015-06-22 init RBC Capital — → Outperform $97
2015-06-16 main Cantor Fitzgerald — → Buy $95
2015-04-15 main Cantor Fitzgerald — → Buy $65
2015-03-31 main Cantor Fitzgerald — → Buy $51
2014-08-13 main Cantor Fitzgerald — → Buy $30
2014-03-10 init William Blair — → Outperform —
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2022-12-31 2021-12-31
Total Revenue
316.61
+84.56%
171.55
Operating Revenue
316.61
+84.56%
171.55
Cost Of Revenue
94.94
+125.07%
42.18
Reconciled Cost Of Revenue
94.94
+125.07%
42.18
Gross Profit
221.67
+71.35%
129.37
Operating Expense
140.71
+11.15%
126.60
Research And Development
34.09
-33.52%
51.27
Selling General And Administration
106.63
+41.56%
75.32
Total Expenses
235.65
+39.62%
168.78
Operating Income
80.96
+2823.80%
2.77
Total Operating Income As Reported
80.96
+2823.80%
2.77
EBITDA
77.50
+9050.18%
0.85
Normalized EBITDA
77.50
+9050.18%
0.85
Reconciled Depreciation
12.02
+219.79%
3.76
EBIT
65.48
+2347.79%
-2.91
Net Income
35.64
+513.14%
-8.63
Pretax Income
61.43
+1450.77%
-4.55
Net Non Operating Interest Income Expense
-3.77
-251.07%
-1.07
Interest Expense Non Operating
4.04
+147.40%
1.64
Net Interest Income
-3.77
-251.07%
-1.07
Interest Expense
4.04
+147.40%
1.64
Interest Income Non Operating
0.27
-51.61%
0.56
Interest Income
0.27
-51.61%
0.56
Other Income Expense
-15.75
-152.37%
-6.24
Other Non Operating Income Expenses
-15.75
-152.37%
-6.24
Tax Provision
25.79
+532.29%
4.08
Tax Rate For Calcs
0.00
-22.22%
0.00
Tax Effect Of Unusual Items
0.00
0.00
Net Income Including Noncontrolling Interests
35.64
+513.14%
-8.63
Net Income From Continuing Operation Net Minority Interest
35.64
+513.14%
-8.63
Net Income From Continuing And Discontinued Operation
35.64
+513.14%
-8.63
Net Income Continuous Operations
35.64
+513.14%
-8.63
Normalized Income
35.64
+513.14%
-8.63
Net Income Common Stockholders
35.64
+513.14%
-8.63
Diluted EPS
2.73
+513.64%
-0.66
Basic EPS
2.76
+518.18%
-0.66
Basic Average Shares
12.93
-0.90%
13.05
Diluted Average Shares
13.07
+0.11%
13.05
Diluted NI Availto Com Stockholders
35.64
+513.14%
-8.63
Line Item Trend 2022-12-31 2021-12-31
Total Assets
406.16
+60.07%
253.73
Current Assets
188.75
+9.36%
172.61
Cash Cash Equivalents And Short Term Investments
55.32
-43.35%
97.66
Cash And Cash Equivalents
55.32
-43.35%
97.66
Receivables
73.44
+56.90%
46.81
Accounts Receivable
72.44
+76.04%
41.15
Other Receivables
1.00
+188.47%
0.35
Inventory
47.79
+118.16%
21.91
Raw Materials
12.35
+68.76%
7.32
Work In Process
14.06
+45.50%
9.67
Finished Goods
21.38
+334.15%
4.92
Prepaid Assets
8.94
+85.05%
4.83
Other Current Assets
3.26
+132.79%
1.40
Total Non Current Assets
217.41
+167.99%
81.13
Net PPE
1.17
-28.61%
1.64
Gross PPE
7.77
+2.34%
7.59
Accumulated Depreciation
-6.60
-10.85%
-5.96
Properties
0.00
0.00
Machinery Furniture Equipment
2.60
+0.00%
2.60
Other Properties
4.01
+4.64%
3.83
Leases
1.16
+0.00%
1.16
Goodwill And Other Intangible Assets
163.36
+224.04%
50.41
Goodwill
45.03
+13.31%
39.74
Other Intangible Assets
118.33
+1008.87%
10.67
Non Current Deferred Assets
27.15
+44.41%
18.80
Non Current Deferred Taxes Assets
27.15
+44.41%
18.80
Other Non Current Assets
25.73
+150.36%
10.28
Total Liabilities Net Minority Interest
172.60
+123.35%
77.28
Current Liabilities
111.09
+49.36%
74.38
Payables And Accrued Expenses
92.46
+123.97%
41.28
Payables
46.38
+115.56%
21.52
Accounts Payable
18.99
+15.59%
16.43
Other Payable
22.20
+336.68%
5.08
Current Accrued Expenses
46.08
+133.12%
19.77
Total Tax Payable
5.18
0.00
Income Tax Payable
5.18
0.00
Current Debt And Capital Lease Obligation
7.78
-71.08%
26.92
Current Debt
6.25
-75.59%
25.61
Other Current Borrowings
6.25
-75.59%
25.61
Current Capital Lease Obligation
1.53
+17.19%
1.31
Other Current Liabilities
10.84
+75.52%
6.18
Total Non Current Liabilities Net Minority Interest
61.51
+2018.95%
2.90
Long Term Debt And Capital Lease Obligation
56.22
+1835.81%
2.90
Long Term Debt
56.22
—
Long Term Capital Lease Obligation
3.79
+30.48%
2.90
Other Non Current Liabilities
5.30
+82.47%
2.90
Stockholders Equity
233.56
+32.36%
176.45
Common Stock Equity
233.56
+32.36%
176.45
Capital Stock
0.02
+5.88%
0.02
Common Stock
0.02
+5.88%
0.02
Preferred Stock
0.00
0.00
Share Issued
17.57
+3.94%
16.90
Ordinary Shares Number
13.02
+1.76%
12.79
Treasury Shares Number
4.55
+10.73%
4.11
Additional Paid In Capital
366.26
+12.43%
325.78
Retained Earnings
111.50
+46.98%
75.86
Gains Losses Not Affecting Retained Earnings
-1.11
-1082.98%
-0.09
Treasury Stock
243.12
+8.00%
225.11
Other Equity Adjustments
-1.11
-1082.98%
-0.09
Total Equity Gross Minority Interest
233.56
+32.36%
176.45
Total Capitalization
289.78
+64.22%
176.45
Working Capital
77.67
-20.93%
98.23
Invested Capital
296.03
+46.50%
202.06
Total Debt
64.00
+137.78%
26.92
Net Debt
7.14
—
Capital Lease Obligations
1.53
+17.19%
1.31
Net Tangible Assets
70.20
-44.30%
126.04
Tangible Book Value
70.20
-44.30%
126.04
Notes Receivable
0.00
-100.00%
5.31
Line Item Trend 2022-12-31 2021-12-31
Operating Cash Flow
50.70
+79.67%
28.22
Cash Flow From Continuing Operating Activities
50.70
+79.67%
28.22
Net Income From Continuing Operations
35.64
+513.14%
-8.63
Depreciation Amortization Depletion
12.02
+219.79%
3.76
Depreciation
0.65
-15.45%
0.76
Amortization Cash Flow
11.38
+279.77%
3.00
Depreciation And Amortization
12.02
+219.79%
3.76
Amortization Of Intangibles
11.38
+279.77%
3.00
Other Non Cash Items
1.45
-31.91%
2.13
Stock Based Compensation
16.45
-15.87%
19.55
Deferred Tax
-8.32
-130.07%
-3.62
Deferred Income Tax
-8.32
-130.07%
-3.62
Operating Gains Losses
9.86
+79.85%
5.48
Gain Loss On Investment Securities
0.96
+240.23%
-0.69
Change In Working Capital
-16.40
-272.00%
9.54
Change In Receivables
-30.83
-423.56%
9.53
Changes In Account Receivables
-30.83
-423.56%
9.53
Change In Inventory
-8.34
+39.72%
-13.83
Change In Prepaid Assets
-5.16
-86.10%
-2.77
Change In Payables And Accrued Expense
46.55
+159.57%
17.93
Change In Accrued Expense
43.58
+460.88%
7.77
Change In Payable
2.97
-70.81%
10.16
Change In Account Payable
2.97
-70.81%
10.16
Change In Other Working Capital
-18.62
-1309.84%
-1.32
Investing Cash Flow
-86.83
-1531.22%
-5.32
Cash Flow From Continuing Investing Activities
-86.83
-1531.22%
-5.32
Net PPE Purchase And Sale
-0.18
+44.89%
-0.32
Purchase Of PPE
-0.18
+44.89%
-0.32
Capital Expenditure
-0.18
+44.89%
-0.32
Net Investment Purchase And Sale
-12.50
0.00
Purchase Of Investment
-12.50
0.00
Net Business Purchase And Sale
-74.15
0.00
Purchase Of Business
-74.15
0.00
Net Other Investing Changes
—
-5.00
Financing Cash Flow
-6.21
+78.13%
-28.39
Cash Flow From Continuing Financing Activities
-6.21
+78.13%
-28.39
Net Issuance Payments Of Debt
12.76
+259.55%
-8.00
Issuance Of Debt
80.00
0.00
Repayment Of Debt
-67.24
-740.45%
-8.00
Long Term Debt Issuance
50.00
0.00
Long Term Debt Payments
-52.24
-552.95%
-8.00
Net Long Term Debt Issuance
-2.24
+72.05%
-8.00
Short Term Debt Issuance
30.00
0.00
Short Term Debt Payments
-15.00
0.00
Net Short Term Debt Issuance
15.00
0.00
Net Common Stock Issuance
-18.00
+15.13%
-21.21
Common Stock Payments
-18.00
+15.13%
-21.21
Repurchase Of Capital Stock
-18.00
+15.13%
-21.21
Proceeds From Stock Option Exercised
1.75
-27.15%
2.40
Net Other Financing Charges
-2.72
-72.23%
-1.58
Changes In Cash
-42.34
-670.34%
-5.50
Beginning Cash Position
97.66
-5.33%
103.16
End Cash Position
55.32
-43.35%
97.66
Free Cash Flow
50.52
+81.11%
27.90
Interest Paid Supplemental Data
1.73
+44.19%
1.20
Income Tax Paid Supplemental Data
28.41
+183.96%
10.01
Earnings Losses From Equity Investments
4.46
-27.76%
6.17
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category